Why did SYRE miss Q2 and Q4 forecasts in 2024?

Spyre Therapeutics (SYRE) missed its Q2 and Q4 forecasts in 2024 due to several factors: 1. **Calculation Errors in Financial Statements**: The company had to revise its financial statements for the fiscal year 2023 and the first three quarters of 2024 because of errors in calculating net loss per share. This indicates a need for better accounting practices and internal controls. 2. **Revenue Shortfall**: Although the company's total revenue showed a year-over-year growth in Q4 2024, it still fell short of the forecast. This could be attributed to specific business segments underperforming or certain products not meeting sales expectations. 3. **Net Income Growth**: The net income growth rate in Q4 2024 was positive, but the actual net income was negative, which might have contributed to the missed forecast. A negative net income indicates the company experienced significant losses during the period, which could be a result of high research and development expenses, marketing costs, or operational inefficiencies. In summary, Spyre Therapeutics' misses in Q2 and Q4 2024 can be attributed to calculation errors, revenue shortfall and net income growth. These factors suggest that while the company is making progress in some areas, it still has significant challenges to overcome in order to meet financial forecasts.